Singapore, 6 June 2023 - Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research ...
Even after completing treatment for tuberculosis (TB), some patients may remain vulnerable to further lung infections.
FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for ...
Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% About AN2 Therapeutics, Inc. AN2 ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ...
Background. Mycobacterium abscessus and Mycobacterium massiliense, which cause lung disease, are variable in their clinical manifestation and progression. We hypothesized that mycobacterial genotypes ...
(RTTNews) - AN2 Therapeutics Inc. (ANTX) announced that the U.S. FDA has cleared its investigator-initiated trial evaluating Epetraborole in 90 patients with Mycobacterium abscessus lung disease, ...
Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results